Quick Asked: Oxurion Nv Contact Us?

Are you searching for Oxurion Nv Contact Us? By using our below available official links ( which are always up to date), you can find contact information without any difficulty. It may list Phone number, Mobile phone, Email Address & Customer service information.
Last update: 03 May, 2024 157 Views

Where is oxoxurion based? Oxurion is headquartered in Leuven, Belgium, and is listed on Euronext Brussels under the symbol OXUR.

Whats new with oxoxurion nv xr 317? Oxurion NV announces full enrollment of its Phase 2 trial evaluating... The study evaluates the efficacy and safety of THR-317 for the treatment of Macular Telangiectasia Type 1. This is a rare disease that affects the macula and can lead to vision loss.

Who is the ceo of oxurion? Before joining Oxurion as CEO in 2008, Patrik was Head of Roche's Global Insulin Infusion business. Prior to this, he was President and CEO of Disetronic Medical Systems Inc, a medical device company based in Minneapolis, USA.

Is oxurion nvs thr 149 effective for dme? Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME. Oxurion NV announces full enrollment of its Phase 2 trial evaluating... The study evaluates the efficacy and safety of THR-317 for the treatment of Macular Telangiectasia Type 1.

Listing Results Oxurion Nv Contact Us? Question Answers

Oxurion Crunchbase Company Profile & Funding

Last Funding Type Grant. Legal Name Oxurion NV. Stock Symbol FRA:TG4. Company Type For Profit. Contact Email [email protected]. Phone Number +32 16 75 13 10. Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients

Investors Oxurion — Advancing Science. Enhancing Vision

Investor relations contact. Gaston Geenslaan 1. B-3001 Heverlee. Belgium. Tel: +32 (0) 16 75 13 10. [email protected].

Oxurion NV Reports First Patient Dosed in Phase 2 study

Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) THR-149 is a potent plasma kallikrein inhibitor in development for DME for up to 40% of patients who respond sub-optimally to anti-VEGF therapy.

OXURION to Present at the Lytham Partners Fall 2021

Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic

Did the information help you? If so, please share!
If you think the information on this page has been helpful to you, would you be willing to share it? Your sharing is the driving force for our continuous work.
  1. Home ›
  2. O ›
  3. Oxurion Nv Contact Us?